Joel McIntosh

Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development

Daqing Sun, Zhihong Li, Yosup Rew et al. · Journal of Medicinal Chemistry · 2014 · 290 citations · Full text

Structure-Based Drug Design of RN486, a Potent and Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis

Yan Lou, Xiaochun Han, A. Kuglstatter et al. · Journal of Medicinal Chemistry · 2014 · 106 citations

Pharmaceutical Science, Tyrosine Kinase, Immunology +18

Design and Synthesis of 4-Azaindoles as Inhibitors of p38 MAP Kinase

Alejandra Trejo, Humberto Arzeno, Michelle F. Browner et al. · Journal of Medicinal Chemistry · 2003 · 94 citations · Full text

Combinatorial Chemistry, Bioorganic Chemistry, P38 Map Kinase +17

Selective and Potent Morpholinone Inhibitors of the MDM2–p53 Protein–Protein Interaction

Ana Z. González, John Eksterowicz, Michael D. Bartberger et al. · Journal of Medicinal Chemistry · 2014 · 83 citations · Full text

Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies

Daniel Robbins, Mark Noviski, Ying Siow Tan et al. · Journal of Medicinal Chemistry · 2024 · 78 citations · Full text